New market study, "Oman Pharmaceuticals & Healthcare Report Q4 2014", has been published

Despite its small size in comparison with other GCC countries, Oman will remain an attractive market to multinational pharmaceutical companies due to the high demand for patented medicines, increases in non-communicable diseases and ageing population. Increasing infrastructure, a higher healthcare budget and an enhanced potential for medical tourism are all positive developments this quarter. S table political and economic environment s are also attractive features of this market.

Headline Expenditure Projections

* Pharmaceuticals: OMR187mn (USD487mn) in 2013 to OMR199mn (USD518mn) in 2014; 6.5% in local currency and US dollar terms. Forecast broadly in line with Q314.
* Healthcare: OMR831mn (USD2.16bn) in 2013 to OMR891mn (USD2.31bn) in 2014; +7.2% in local currency and US dollar terms. Forecast revised slightly upwards due to macroeconomic changes.

Risk/Reward Rating

Full Report Details at
- http://www.fastmr.com/prod/888138_oman_pharmaceuticals_healthcare_report_q4_2014.aspx?afid=301

Oman has limited longer-term commercial potential due to its small population and the fact that the government is responsible for the bulk of healthcare costs, which will increase the need for cost containment in the coming years. In Q414, Oman's Pharmaceutical Risk/Reward Rating (RRR) scores 49.3 out of 100, which has seen the country move down one position to 10th in the Middle East and Africa matrix out of 31 countries.

Key Trends And Developments

Oman's Ministry of Health unveiled a comprehensive guide on private healthcare institutes - known as the Health Service Directory - in August 2014. The directory has been written in Arabic and English, and is divided into four sections, covering private healthcare establishments, pharmacies, medical equipment suppliers and support services. The directory has been created through a partnership between public and private sector institutions, according to the Ministry of Health's advisor for health affairs.

In July 2014, it was announced that Oman had more than doubled planned spending for healthcare in the 2014 budget, to USD3.4bn...

The Oman Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Oman Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Omani pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Oman to test other views - a key input for successful budgeting and strategic business planning in the Omani pharmaceutical and healthcare market.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- South Korea Pharmaceuticals & Healthcare Report Q4 2014
- Sweden Pharmaceuticals & Healthcare Report Q4 2014
- Kenya Pharmaceuticals & Healthcare Report Q4 2014
- Bulgaria Pharmaceuticals & Healthcare Report Q4 2014
- Argentina Pharmaceuticals & Healthcare Report Q4 2014